Shannon was 42 years old when she came to Dr. Lamb’s clinic in late October 2022. She had lived with a formal Multiple Sclerosis diagnosis for 17 years. Those years had brought progressive, relentless disability.

On her left side, she experienced constant migraines. Her left eye had been partially blinded by optic neuritis, a loss of vision that had persisted for years. She felt the MS hug constantly: a crushing, band-like pressure across her thoracic spine as if someone were always squeezing her from the inside. Her left arm and leg were weak. She experienced tingling and numbness that never fully resolved. She had vertigo bad enough to cause falls. Her bowel and bladder function had become unpredictable and limiting. Despite years of infusion therapy and regular neurological monitoring at a tertiary MS clinic, her trajectory was downward.

Her medical team expected the decline to continue. They told her to prepare for worsening disability, for the eventual loss of use of her legs.

But Shannon’s history held a clue that standard neurological evaluation had not connected to her MS symptoms.

The Collision and Its Aftermath

Years earlier, around 2005, Shannon had been in a head-on motor vehicle collision. The impact had thrown her into a severe, asymmetric whiplash injury concentrated on her left side. The injury affected her cervical and thoracic spine. In the immediate aftermath, she had recovered from the acute phase. But her neuromuscular system had not fully resolved the structural damage. Deep fibrosis had formed. Vertebrae had shifted. Nerve roots had become tethered.

What made this significant was that Shannon’s MS symptoms followed a strikingly left-dominant pattern. Her migraines: left side. Her vision loss: left eye. Her weakness and numbness: left arm and leg. Her balance issues: left-sided falls. The MS hug: left-sided pressure.

The anatomical distribution of her symptoms matched the location of her old whiplash injury.

Comprehensive Neuromyofascial Assessment

In October 2022, Dr. Lamb performed a comprehensive neuromyofascial assessment. This detailed structural evaluation looked beyond the MS diagnosis to identify mechanical factors that might be contributing to Shannon’s symptom burden.

The assessment revealed significant spinal pathology: deep fibrosis throughout the cervical and thoracic regions, thoracic retrolisthesis, nerve root tethering, and widespread myofascial restriction. These mechanical findings did not cause her MS. But they appeared to be amplifying her neurological symptoms and limiting her functional recovery.

The hypothesis was straightforward: if these mechanical restrictions could be identified and released, Shannon’s symptom burden might decrease substantially, regardless of whether the underlying demyelinating disease changed.

The Intervention and Immediate Response

On December 22, 2022, Shannon received her first targeted treatment. The procedure focused on the specific spinal segments where fibrosis and tethering had been identified in the cervical, thoracic, and lumbar regions. The intervention was designed to release mechanical restriction and decompress tethered nerve structures.

Within minutes, before she left the treatment room that day, Shannon noticed changes.

In her own words from the video recorded that day: “I feel like there’s no pressure. There’s no headache. When’s the last time you had no headache? I can’t remember. I feel like my vision’s clear. I feel like it doesn’t have that weird blur I had. Everything’s lighter. I feel like I have more feeling and I’m lighter.”

Her left arm, which had been restricted to 90 to 120 degrees of motion, could suddenly lift fully overhead. The MS hug was gone. Her balance, which had been shaky, improved immediately. Her hands, which had been numb and tingling since diagnosis, had restored sensation and function.

These immediate improvements were dramatic. But Shannon understood, and Dr. Lamb explained, that there was more work to do.

Building the Gains

Over the following weeks, Shannon received additional targeted treatments in early January 2023. Each treatment addressed different segments identified in her assessment. Each treatment produced functional improvements that stacked on top of the previous gains. With each intervention, more of her neuromuscular system found relief.

The Sustained Recovery

By February 2023, six weeks after her first treatment, Shannon returned for follow-up. The improvements had held steady. She reported no headaches, something she could not have said in 17 years. Her vision remained clear. The MS hug had not returned. Her strength and sensation continued to improve. She was not taking additional medications beyond her regular MS infusion therapy, scheduled for every six months as part of her ongoing neurological care.

By June 2023, six months after her initial treatment, Shannon’s functional recovery had consolidated into her new normal.

She could use stairs independently, something she had not been able to do safely in years. She could wear high heels for the first time in years. She could dance. She could stand on one leg with stability. She could lift both arms fully overhead without restriction. She reported no remaining MS symptoms.

Most remarkably, she was living without the daily fear of progressive decline that had defined her previous 17 years.

At her six-month follow-up, Shannon reported: “I feel better and free than I did. Free. I feel like I have a brand new body, and I’m able to advance back into this area and system. I can do that being utilized for the first time before you able to use stairs. I myself… I feel so good and right lately. That is all they’ve done.”

What This Means

For context: in MS, natural relapse recovery typically unfolds over three to six months. Patients often reach a plateau and do not return to full baseline. The speed and breadth of Shannon’s functional improvement, across vision, motor function, balance, sensation, and autonomic domains, within weeks, then sustained and continuing to improve through six months, is atypical for standard MS natural history.

This does not mean Shannon’s underlying MS diagnosis has been cured or reversed. The demyelinating disease process remains unchanged. What it suggests is that a treatable mechanical and neuromyofascial component was superimposed on her neurological condition, and that removing mechanical restriction created space for substantial functional recovery.

Shannon’s case demonstrates that patients with complex neurological diagnoses may benefit from systems-informed assessment that identifies and addresses mechanical contributors alongside standard medical management.

Today

As of 2026, Shannon continues to maintain the functional gains achieved through treatment, with ongoing quality of life improvements. She remains engaged with her neurological care team and continues to benefit from periodic maintenance treatment as part of her comprehensive care approach.